Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats

Psychopharmacology

Volumn 164, Issue 1, 2002, Pages 93-107

  Marona Lewicka, Danuta ^a   Kurrasch Orbaugh, Deborah M ^a   Selken, Jennifer R ^a   Cumbay, Medhane G ^a   Lisnicchia, Joshua G ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

5 HT; 5 HT1A; Behavior; Dopamine; Drug discrimination; Lisuride; Lower lip retraction; Rat

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL) N METHYL 2 BUTANAMINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4 IODO N [2 [4 (METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N 2 PYRIDYNYLBENZAMIDE; 5 METHOXY 6 METHYL 2 AMINOINDAN; AMPHETAMINE; CYCLIC AMP; HALOPERIDOL; INDAN DERIVATIVE; KETANSERIN; LISURIDE; LY 293284; LYSERGIDE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BODY POSTURE; BODY TEMPERATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BODY TEMPERATURE; CHO CELLS; CRICETINAE; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LISURIDE; LYSERGIC ACID DIETHYLAMIDE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS;

EID: 0036402523     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1141-z     Document Type: Article

References (101)

1. Adams LM, Geyer MG (1985) Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide. Pharmacol Biochem Behav 23:461-468
2. 1A receptors. Soc Neurosci Abstr 20:633.4
3. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5
4. Allain H, Destee A, Petit H, Schuck S, Bentue-Ferrer D, Le Cavorzin P (2000) Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. Eur Neurol 44:22-30
5. 2 agonists in rats. Pharmacol Toxicol 64:165-172
6. Assie M-B, Cosi C, Koek W (1997) 5-HT1A agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147
7. 1A receptors. Br J Pharmacol 100:793-799
8. Bagdy G, To CT (1997) Comparison of the relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tai flicks. Eur J Pharmacol 323:53-58
9. 3H-lisuride to adrenergic and serotonergic receptors. Life Sci 29:909-916
10. Bedard P, Pycock CJ (1977) "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology 16:633-670
11. 1A receptors induces lower lip retraction. Pharmacol Biochem Behav 33:821-827
12. Berendsen HHG, Bourgondien FGM, Broekkamp CLE (1994) Role of dorsal and median raphe nuclei in lower lip retraction in rats. Eur J Pharmacol 263:315-318
13. Berg KA, Clarke WP, Sailstad WP, Saltzman A, Maayani S (1994) Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol Pharmacol 46:477-484
14. 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther 258:58-65
15. Brauer LH, Goudie AJ, de Wit H (1997) Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2-13
16. Burris KD, Breeding M, Sanders-Bush E (1991) (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 258:891-896
17. Callahan PM, Appel JB (1990) Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using three-choice, drug discrimination procedure. Psychopharmacology 100:13-18
18. Carruba MO, Mantegazza P (1983) Behavioral pharmacology of ergot derivatives. In: Calne BD, Horowski R, Mc Donald MJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 65-77
19. Carruba MO, Ricciardi S, Negreanu J, Calogero M, Mantegazza P (1980) Effects of lisuride on body temperature of rats and rabbits: relation to microsomal biotransformation and dopaminergic receptor stimulation. Psychopharmacology 70:223-229
20. 2A) receptors in the mediation of discriminative stimulus properties of (±)-DOI in rats. Pol J Pharmacol 49:299-304
21. Colpaert FC, Janssen PAJ (1985) Discriminative stimulus properties of xylazine in rat: discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists. J Pharmacol Exp Ther 235:521-527
22. Cox B, Lee TF (1979) Possible involvement of 5-hydroxytryptamine in dopamine-receptor-mediated hypothermia in rat. J Pharm Pharmacol 31:352-354
23. Cunningham KA, Appel JB (1987) Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD). Psychopharmacology 91:67-73
24. 2 receptors. J Pharmacol Exp Ther 241:147-151
25. Cunningham KA, Callahan PM, Appel JB (1987b) Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT): implications for understanding the actions of novel anxiolytics. Eur J Pharmacol 138:29-36
26. 2 receptors? Pharmacol Biochem Behav 26:901-906
27. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 238:248-253
28. Dickinson SL, Curzon G (1983) Role of dopamine and 5-hydroxytryptamine in stereotyped and non-stereotyped behaviours. Neuropharmacology 22:805-812
29. 1A agonist LY 165163. Psychopharmacology 93:82-86
30. 2C receptors. Psychopharmacology 136:409-414
31. 2C receptors. Synapse 35:144-150
32. Extance K, Goudie AJ (1981) Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology 73:363-370
33. Fink H, Morgenstern R (1985) Locomotor effect of lisuride: a consequence of dopaminergic and serotoninergic actions. Psychopharmacology 85:464-468
34. 1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 270:1270-1281
35. 1A receptors coupled to adenylyl cyclase are a model for postsynaptic receptors in the rat hippocampus. Br J Pharmacol 107:141-145
36. Fuxe K, Fredholm BB, Ogren S, Agnati LF, Hokfelt T, Gustaffson J (1978) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis. Fed Proc 37:2181-2191
37. Glennon RA (1986) Discriminative stimulus properties of serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Life Sci 39:825-830
38. Glennon RA, Hauck AE (1985) Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav 23:937-941
39. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511
40. Glusa E, Markwardt F (1984) Interaction of lisuride with monoamine receptors in human blood platelets. Biochem Pharmacol 33:493-496
41. 1A receptors. Neuropharmacology 25:1307-1313
42. Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K (1977) Clinical effectiveness of lisuride hydrogen maleate: a double-bind trial versus methysergide. Headache 17:54-60
43. Hoffman A (1975) Psychotomimetic drugs: chemical and pharmacological aspects. Acta Physiol Pharmacol 86:134-138
44. Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81:595-602
45. Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen-maleate, an ergot derivative, in mice. Eur J Pharmacol 36:101-108
46. 1A) receptors. Br J Pharmacol 90:92P
47. 1 recognition sites. J Receptor Res 8:59-81
48. Hoyer D, Schoeffter P (1991) 5-HT receptors: subtypes and second messengers. J Receptor Res 11:197-214
49. Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB (2001) D1 dopamine receptors. Int Rev Neurobiol 48:66-138
50. Hutson PH, Donohoe TP, Curzon G (1987) Neurochemical and behavioural evidence for an agonist action of 1-[2-(4-aminophenyl)ethyl]-4-(3-fluoromethylphenyl) piperazine (LY 165,163) at central 5-HT receptors. Eur J Pharmacol 138:215-223
51. 2 receptor sites: drug discrimination and receptor binding studies. Behav Pharmacol 2:105-112
52. 2 receptors: location, pharmacological, pathologic and physiological role. In: Langer SZ, Brunello N, Racagni G, Mendlewicz J (eds) Serotonin receptor subtypes: pharmacological significance and clinical implications. Int Acad Biomed Drug Res, vol 1. Karger, Basel, pp 31-43
53. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-112
54. Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981) Activity of non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73:328-331
55. Marona-Lewicka D, Nichols DE (1994) Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 258:1-13
56. 1A receptors. J Neurochem 74:347-357
57. McMillen BA, Scott SM, Williams HL, Sanghera MK (1987) Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn-Schmiedeberg's Arch Pharmacol 335:454-464
58. 2-adrenoceptors. Eur J Pharmacol 97:151-155
59. Meltzer HY, Maes M (1995) Pindolol pretreatment blocks stimulation of metachlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res 58:89-98
60. Mokler DJ, Commissaris RL, Warner MR, Rech RH (1983) Blockage of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists. J Pharmacol Exp Ther 227:557-562
61. 1A receptor-mediated activity. J Pharmacol Exp Ther 256:973-982
62. Montastruc JL, Rascol O, Senard J-M (1999) Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 14:725-730
63. 1A agonists and antagonists. Pharmacol Biochem Behav 46:141-143
64. Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Furukawa H, Kameyama T (1984) Serotonergic involvement in phencyclidine induced behaviors. Pharmacol Biochem Behav 21:401-414
65. Nichols DE (1976) Structural correlation between apomorphine and LSD: Involvement of dopamine as well as serotonin in the actions of hallucinogens. J Theor 59:167-177
66. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann NY Acad Sci 600:613-625
67. Nichols DE, Hoffman RA, Oberlender RA, Jakob IIIP, Schulgin AT (1986) Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine. Representative of a novel therapeutic class. J Med Chem 29:2009-2016
68. Nordsted C, Fredholm BB (1990) A modification of a protein binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Ann Biochem 189:231-234
69. Odagaki Y, Fuxe K (1995) Pharmacological characterization of the 5-hydroxytryptamine-1A receptor-mediated activation of high-affinity GTP hydrolysis in rat hippocampal membranes. J Pharmacol Exp Ther 274:337-344
70. 1B receptors. Psychopharmacology 132:255-260
71. 1A/dopamine agonist. J Pharmacol Exp Ther 268:1304-1310
72. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35-44
73. Pieri M, Schaffner R, Pieri L, De Prada M, Haefley W (1978) Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD. Life Sci 22:1615-1622
74. Portais P, Dubuc I, Costentin J (1983) Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behavior in rats. Eur J Pharmacol 94:271-280
75. Rabin RA, Regina M, Doat M, Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72:29-37
76. Rex A, Voight JP, Voits M, Fink H (1998) Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 59:677-683
77. Rinne UK (1999) Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motoric fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy. Nervenarzt 70[Suppl 1]:S19-S25
78. Rogawski MA, Aghajanian GK (1979) Response of central monoaminergic neurons to lisuride: comparison with LSD. Life Sci 24:1289-1298
79. Rosenfeld M, Makman MH (1981) The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol Exp Ther 216:526-531
80. Schechter MD (1984) Evidence for a direct dopaminergic effect of lisuride. Pharmacol Biochem Behav 21:185-189
81. Sielbergeld EK, Hruska RE (1979) Lisuride and LSD dopaminergic and serotonergic interactions in the "serotonin syndrome". Psychopharmacology 65:233-237
82. 1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 24:1513-1519
83. 2C receptor. Psychopharmacology 144:248-254
84. 1B agonists. Synapse 1:3-9
85. 3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms. Biochem Pharmacol 45:1003-1009
86. 3H]lisuride labels free receptor and receptor coupled to G protein. J Neurochem 65:1909-1916
87. Svensson L (1985) Effects of 8-OH-DPAT, lisuride and some ergot-related compounds on the acoustic startle response in the rat. Psychopharmacology 85:469-475
88. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213-216
89. Tricklebank MD (1985) The behavioral response to 5-HT receptor agonists and subtypes of the central 5-HT receptor. Trends Pharmacol Sci 5:403-407
90. Uzumaki H, Govoni S, Memo M, Carruba MO, Trabucchi M, Spano PF (1982) Effect of GTP and sodium on rat striatal dopaminergic receptors labeled with lisuride. Brain Res 248:185-187
91. Wachtel H (1978) Inhibition of locomotor activity of rats by low doses of different dopamine (DA) receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol 302:R326
92. Wachtel H (1983) Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride. In: Calne BD, Horowski R, Mc Donald MJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 109-125
93. Wachtel H (1991) Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm 3:151-201
94. Walters JR, Baring MD, Lakoski JM (1979) Effects of ergolines on dopaminergic and serotonergic single unit activity. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, New York, pp 207-221
95. 2 dopamine receptors. Mol Pharmacol 50:966-976
96. Welsh SE, Kachelries WJ, Romano AG, Simansky KJ, Harvey JA (1998) Effects of LSD, ritanserin, 8-OH-DPAT, and lisuride on classical conditioning in the rabbit. Pharmacol Biochem Behav 59:469-475
97. White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol Biochem Behav 24:365-379
98. White FJ, Appel JB (1981) Differentiation of the neuropharmacological effects of d-lysergic acid diethylamide and lisuride hydrogen maleate with a drug discrimination. Fed Proc 40:414
99. White FJ, Appel JB (1982a) Training dose as a factor in LSD-saline discrimination. Psychopharmacology 76:20-25
100. White FJ, Appel JB (1982b) Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. Science 216:535-53
101. Zikan V, Siemonsky M (1960) Mutterkorn alkaloids XVI. Einige N-(D-6-meth-yllisoergolenyl-8)-, N-(D-6-methylergolenyl-8)-und N-(D-6-methylergolin (I)-YL-8)-N′-substitiuerte Harn-stoffe. Collect Czech Chem Commun 25:1922-1928